Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Comirnaty (COVID-19 mRNA vaccine by Year
Comirnaty (COVID-19 mRNA vaccine — BioNTech collaboration) — U.S. revenues ($M) ($M)
Pfizer Comirnaty (COVID-19 mRNA vaccine: $1,663M in FY2025, down 17.0% from a year earlier.
Where the FY2025 figure comes from
“|| Comirnaty | 4,367 | 5,353 | (18%) | (20%) | 1,663 | 2,004 | (17%) | 2,705 | 3,349 | (19%) | (21%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Comirnaty (COVID-19 mRNA vaccine — BioNTech collaboration) — U.S. revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,663 | -17.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 2,004 | -16.6% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 2,404 | -71.1% | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 8,330 | +2.3% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2021 | Dec 31, 2021 | 8,143 | +5,187.7% | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2020 | Dec 31, 2020 | 154 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
Breakdown
What makes up comirnaty (COVID-19 mRNA vaccine
Cite this data
StockData. (2026). Pfizer Comirnaty (COVID-19 mRNA vaccine ($M), annual FY2020–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/comirnaty-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.